Comparison
Both are incretin-based peptides researched for metabolic health and weight management, but Retatrutide adds glucagon receptor agonism to the dual GLP-1/GIP activity of Tirzepatide.
Tirzepatide is marketed as Mounjaro (type 2 diabetes) and Zepbound (weight management). Retatrutide has no approved brand name and remains in Phase 2 clinical trials.
| Attribute | Retatrutide | Tirzepatide |
|---|---|---|
| Full name | Retatrutide (LY3437943) | Tirzepatide (Mounjaro / Zepbound) |
| Class | Triple agonist (GLP-1 / GIP / glucagon) | Dual agonist (GLP-1 / GIP) |
| Mechanism | Activates GLP-1, GIP, and glucagon receptors simultaneously | Activates GLP-1 and GIP receptors; GIP agonism differentiates it from semaglutide |
| Half-life | ~6 days | ~5 days |
| Commonly reported doses | 2–12 mg/week SubQ | 2.5–15 mg/week SubQ (titration-based) |
| Routes | SubQ injection | SubQ injection |
| Primary reported use | Metabolic health, weight management, research-stage compound | FDA-approved for type 2 diabetes and obesity; widely used in research contexts |
The key distinction is retatrutide's glucagon receptor agonism. This third receptor target appears to increase energy expenditure directly — glucagon raises metabolic rate and promotes hepatic glucose output — potentially explaining the greater weight loss depth reported in phase 2 trials compared to tirzepatide. Research has investigated this additional pathway for its potential role in amplifying the metabolic effects seen with dual agonism alone.
Approval status and evidence base differ substantially. Tirzepatide has completed phase 3 trials and received FDA approval for both type 2 diabetes (Mounjaro) and obesity (Zepbound), giving it a far more extensive published dataset. Retatrutide remains in phase 2 development as of the knowledge cutoff, and all use outside of clinical trials is investigational. Researchers working with retatrutide are operating on preliminary phase 2 data only.
GI tolerability profiles for both compounds share common features. Reported side effects in research and anecdotal accounts include nausea, vomiting, constipation, and diarrhoea for both agents, and both require slow, systematic dose titration to manage early tolerability. Retatrutide's additional glucagon agonism may modulate certain GI parameters differently — glucagon itself has pro-motility effects — though the clinical significance of this difference in the context of the full triple-agonist profile is not yet well characterised.
Both compounds act on incretin receptors, but retatrutide extends this to three simultaneous targets:
The balance of these activities in retatrutide is designed so that the hyperglycaemic effect of glucagon agonism is offset by the strong insulinotropic effects of simultaneous GLP-1 and GIP agonism, making the net effect on blood glucose favourable rather than harmful.
Research has investigated both compounds for their potential role in:
Beyond these shared areas, tirzepatide has published data from investigations into non-alcoholic steatohepatitis (NASH) and heart failure with preserved ejection fraction (HFpEF). Retatrutide research to date has focused primarily on its weight reduction and metabolic profile in phase 2 trial populations; broader indication investigations are ongoing or anticipated.
Commonly reported doses range from 2 mg to 12 mg per week for retatrutide, with a slow titration protocol commonly reported in research contexts:
Commonly reported doses range from 2.5 mg to 15 mg per week for tirzepatide, following the titration schedule used in phase 3 trials:
Both compounds are administered via subcutaneous injection, commonly reported as once weekly. Injection sites reported in research protocols include the abdomen, anterior thigh, and upper arm. Rotating injection sites is part of the commonly reported protocol for both agents to minimise local tissue reactions.
Reported side effects in research and anecdotal accounts include the following for both compounds:
Retatrutide's additional glucagon receptor agonism may produce a different nausea profile compared to tirzepatide, as glucagon has known effects on gastric motility. Anecdotal reports suggest some differences in GI tolerability character between the two, though direct comparative data from head-to-head trials is not yet available. Both compounds have reported rare cases of pancreatitis, consistent with the broader GLP-1 agonist class.
Tirzepatide is the more accessible option given its regulatory approval and clinical availability. Researchers and clinicians working within approved indications have access to extensive phase 3 data, established dosing guidance, and pharmaceutical-grade supply. Retatrutide is used by researchers specifically seeking to investigate the triple-agonist mechanism — particularly the additive contribution of glucagon receptor agonism — or when phase 2 data on maximum weight loss depth is the primary research focus. All retatrutide use remains investigational.
Retatrutide and tirzepatide are not typically co-administered. Both target overlapping receptor systems — GLP-1 and GIP — and combining them would not add meaningful mechanistic value while substantially increasing the burden of dose management and side effect risk. Researchers generally select one approach based on their specific investigational focus rather than combining the two. No established co-administration protocol exists in the published literature.
Researchers commonly choose tirzepatide when the focus is a well-characterised dual-agonist effect supported by a full phase 3 dataset, established dosing protocols, and regulatory-grade safety data. Its approval status and broad evidence base make it the default choice for most metabolic health research contexts.
Researchers commonly choose retatrutide when specifically investigating the additional contribution of glucagon receptor agonism to metabolic outcomes, or when exploring the maximum reported weight-loss depth achievable with a triple-agonist approach in a research context. Given its phase 2 status, it is suited to contexts where preliminary data is acceptable and where the glucagon pathway is part of the explicit research question.
Phase 2 data suggests greater reported weight loss depth with retatrutide compared to tirzepatide's phase 3 results. However, direct head-to-head phase 3 comparative data is not yet available, and differences in trial populations, follow-up duration, and dose escalation schedules make cross-study comparisons imprecise.
Retatrutide is not approved by the FDA or other major regulatory agencies as of the knowledge cutoff. It remains in phase 2 clinical development. Tirzepatide is FDA-approved under the brand names Mounjaro (type 2 diabetes) and Zepbound (obesity). All retatrutide use outside of approved clinical trials is investigational.
Semaglutide is a GLP-1 mono-agonist only. Both tirzepatide and retatrutide add GIP receptor agonism to the GLP-1 base mechanism — this dual agonism is associated with greater metabolic effects than GLP-1 agonism alone. Retatrutide further adds glucagon receptor agonism, targeting all three receptors simultaneously. Research has investigated this progression from mono- to dual- to triple-agonism for its potential role in producing incrementally greater metabolic and weight management outcomes.